公开(公告)号：US07811570B2

公开(公告)日：2010-10-12

申请号：US11229872

申请日：2005-09-20

Applicant: David M. Goldenberg

Inventor： David M. Goldenberg

IPC: A61K39/395

CPC classification number: G01R33/5601 ,  A61K49/16 ,  A61K51/10 ,  A61K51/1018 ,  A61K51/1036 ,  A61K51/1039 ,  A61K51/1045 ,  A61K51/1057 ,  A61K51/1072 ,  A61K2123/00 ,  B82Y5/00 ,  Y10S424/81 ,  Y10S530/868

Abstract: Provided are methods and compositions for detecting and treating normal, hypoplastic, ectopic or remnant tissue, organ or cells in a mammal. The method comprises parenterally injecting a mammalian subject, at a locus and by a route providing access to said tissue or organ, with an composition comprising antibody/fragment which specifically binds to targeted organ, tissue or cell. The antibody/fragment may be administered alone, or labeled or conjugated with an imaging, therapeutic, cytoprotective or activating agent.

Abstract translation: 提供了用于检测和治疗哺乳动物中正常，发育不全，异位或残余组织，器官或细胞的方法和组合物。 该方法包括在一个位点和通过提供通向所述组织或器官的途径的哺乳动物受试者肠胃外注射包含特异性结合靶向器官，组织或细胞的抗体/片段的组合物。 抗体/片段可以单独施用，或者与成像，治疗，细胞保护或活化剂标记或缀合。

公开(公告)号：US06592868B1

公开(公告)日：2003-07-15

申请号：US08485622

申请日：1995-06-07

Applicant: Seth Lederman ,  Leonard Chess ,  Michael J. Yellin

Inventor： Seth Lederman ,  Leonard Chess ,  Michael J. Yellin

IPC: A61K39395

CPC classification number: C07K14/705 ,  A61K38/00 ,  A61K39/00 ,  A61K47/68 ,  A61K47/6849 ,  A61K51/1039 ,  A61K51/1087 ,  A61K2123/00 ,  C07K14/70575 ,  C07K16/2875 ,  C07K2317/24 ,  C07K2319/00 ,  C12N5/0694 ,  Y02A50/401 ,  Y10S514/885

Abstract: This invention provides methods of treating autoimmune diseases, including those selected from the group consisting of rheumatoid arthritis, Myasthenia gravis, systemic lupus erythematosus, Graves' disease, idiopathic thrombocytopenia purpura, hemolytic anemia and diabetes mellitus with 5C8-specific antibodies.

Abstract translation: 本发明提供了治疗自身免疫性疾病的方法，包括选自类风湿性关节炎，重症肌无力，系统性红斑狼疮，格雷夫斯病，特发性血小板减少性紫癜，溶血性贫血和糖尿病患者中的5C8特异性抗体。

公开(公告)号：US06451310B1

公开(公告)日：2002-09-17

申请号：US08484137

申请日：1995-06-07

Applicant: Seth Lederman ,  Leonard Chess ,  Michael J. Yellin

Inventor： Seth Lederman ,  Leonard Chess ,  Michael J. Yellin

IPC: A61K39395

CPC classification number: C07K14/705 ,  A61K38/00 ,  A61K39/00 ,  A61K47/68 ,  A61K47/6849 ,  A61K51/1039 ,  A61K51/1087 ,  A61K2123/00 ,  C07K14/70575 ,  C07K16/2875 ,  C07K2317/24 ,  C07K2319/00 ,  C12N5/0694 ,  Y02A50/401 ,  Y10S514/885

Abstract: This invention provides a method of inhibiting an allergic response in a subject by inhibiting T cell activation of B cells, wherein said method comprises administering to the subject an antibody capable of binding to a protein which is specifically recognized by monoclonal antibody 5C8 produced by the hybridoma having ATCC Accession No. HB 10916.

Abstract translation: 本发明提供了通过抑制B细胞的T细胞活化来抑制受试者的过敏反应的方法，其中所述方法包括向受试者施用能够与由杂交瘤产生的单克隆抗体5C8特异性识别的蛋白质结合的抗体 具有ATCC保藏号HB 10916。

公开(公告)号：US5776095A

公开(公告)日：1998-07-07

申请号：US456914

申请日：1995-06-01

Applicant: Milton David Goldenberg

Inventor： Milton David Goldenberg

IPC: A61K49/00 ,  A61B5/05 ,  A61B5/055 ,  A61K39/395 ,  A61K45/00 ,  A61K47/48 ,  A61K49/16 ,  A61K51/04 ,  A61K51/08 ,  A61K51/10 ,  A61P35/00 ,  A61P43/00 ,  C07K20060101 ,  C07K16/18 ,  C07K16/28 ,  C07K17/00 ,  G01N33/53 ,  G01R33/28 ,  G01R33/48 ,  A61N1/30 ,  A61K51/00

CPC classification number: G01R33/5601 ,  A61K49/16 ,  A61K51/10 ,  A61K51/1018 ,  A61K51/1036 ,  A61K51/1039 ,  A61K51/1045 ,  A61K51/1057 ,  A61K51/1072 ,  B82Y5/00 ,  A61K2123/00 ,  Y10S424/81 ,  Y10S530/868

Abstract: Provided are methods and compositions for detecting and treating normal, hypoplastic, ectopic or remnant tissue, organ or cells in a mammal. The method comprises parenterally injecting a mammalian subject, at a locus and by a route providing access to said tissue or organ, with an composition comprising antibody/fragment which specifically binds to targeted organ, tissue or cell. The antibody/fragment may be administered alone, or labeled or conjugated with an imaging, therapeutic, cytoprotective or activating agent.

公开(公告)号：US5759546A

公开(公告)日：1998-06-02

申请号：US192480

申请日：1994-02-04

Applicant: Andrew D. Weinberg ,  Arthur A. Vandenbark

Inventor： Andrew D. Weinberg ,  Arthur A. Vandenbark

IPC: G01N33/53 ,  A61K38/00 ,  A61K39/395 ,  A61K47/48 ,  A61K49/00 ,  A61K51/00 ,  A61K51/10 ,  A61P29/00 ,  A61P35/02 ,  A61P37/00 ,  A61P37/06 ,  C07H21/04 ,  C07K14/705 ,  C07K14/725 ,  C07K14/73 ,  C07K16/28 ,  C12N15/09 ,  C12P21/02 ,  C12P21/08 ,  C12R1/91 ,  G01N33/577 ,  C07K19/00

CPC classification number: A61K49/0058 ,  A61K47/48561 ,  A61K51/1039 ,  C07K14/70578 ,  C07K16/2878 ,  A61K38/00 ,  C07K2319/00 ,  Y10S530/866 ,  Y10S530/867 ,  Y10S530/868

Abstract: A method for the selective depletion of activated CD4.sup.+ T-cells in vivo by using immunotoxins comprising the OX-40 antibody conjugated to a toxic molecule (such as Ricin-A chain). The administration of these specific immunotoxins is used therapeutically to deplete autoimmune reactive CD4.sup.+ T-cells which have been implicated in diseases including Multiple Sclerosis, Rheumatoid Arthritis, Sarcoidosis, and Autoimmune Uveitis. This type of therapy is also beneficial for eradicating CD4.sup.+ T-cell lymphomas and alloreactive CD4.sup.+ T-cells involved with a transplantation reaction. The use of the human form of the OX-40 antibody will also help in the early diagnosis of all the diseases mentioned above.

Abstract translation: 通过使用包含与毒性分子缀合的OX-40抗体（例如蓖麻毒素A链）的免疫毒素在体内选择性消耗活化的CD4 + T细胞的方法。 这些特异性免疫毒素的施用在治疗上用于消除已涉及包括多发性硬化，类风湿关节炎，结节病和自身免疫性葡萄膜炎在内的疾病的自身免疫反应性CD4 + T细胞。 这种治疗方法也有利于根除与移植反应相关的CD4 + T细胞淋巴瘤和同种异体反应性CD4 + T细胞。 OX-40抗体的人体形态的使用也有助于早期诊断上述所有疾病。

公开(公告)号：US20240343803A1

公开(公告)日：2024-10-17

申请号：US18292480

申请日：2022-07-28

Applicant: SHANDONG SIMCERE BIOPHARMACEUTICAL CO., LTD.

Inventor： Xiaofeng ZHAO ,  Lei LIU ,  Yayuan FU ,  Zhuoxiao CAO ,  Renhong TANG ,  Jinsheng REN ,  Yang LIU

IPC: C07K16/28 ,  A61K47/68 ,  A61K49/00 ,  A61K51/10 ,  A61P35/00

CPC classification number: C07K16/2818 ,  A61K47/6849 ,  A61K49/0002 ,  A61K51/1039 ,  A61P35/00 ,  C07K16/2803 ,  C07K16/2827 ,  C07K2317/24 ,  C07K2317/31

Abstract: The present disclosure relates to a bispecific antibody capable of specifically binding PVRIG and TIGIT, which can modulate the function of immune cells and can be used as a drug to treat diseases related to immune abnormalities, such as tumors.

公开(公告)号：US20110117105A1

公开(公告)日：2011-05-19

申请号：US12987814

申请日：2011-01-10

Applicant: Milton David GOLDENBERG

Inventor： Milton David GOLDENBERG

IPC: A61K39/395 ,  A61P37/02

CPC classification number: G01R33/5601 ,  A61K49/16 ,  A61K51/10 ,  A61K51/1018 ,  A61K51/1036 ,  A61K51/1039 ,  A61K51/1045 ,  A61K51/1057 ,  A61K51/1072 ,  A61K2123/00 ,  B82Y5/00 ,  Y10S424/81 ,  Y10S530/868

Abstract: Provided are methods and compositions for detecting and treating normal, hypoplastic, ectopic or remnant tissue, organ or cells in a mammal. The method comprises parenterally injecting a mammalian subject, at a locus and by a route providing access to said tissue or organ, with an composition comprising antibody/fragment which specifically binds to targeted organ, tissue or cell. The antibody/fragment may be administered alone, or labeled or conjugated with an imaging, therapeutic, cytoprotective or activating agent.

Abstract translation: 提供了用于检测和治疗哺乳动物中正常，发育不全，异位或残余组织，器官或细胞的方法和组合物。 该方法包括在一个位点和通过提供通向所述组织或器官的途径的哺乳动物受试者肠胃外注射包含特异性结合靶向器官，组织或细胞的抗体/片段的组合物。 抗体/片段可以单独施用，或者与成像，治疗，细胞保护或活化剂标记或缀合。

公开(公告)号：US20060067885A1

公开(公告)日：2006-03-30

申请号：US11229872

申请日：2005-09-20

Applicant: David Goldenberg

Inventor： David Goldenberg

IPC: A61K51/00 ,  A61M36/14 ,  A61K49/00

CPC classification number: G01R33/5601 ,  A61K49/16 ,  A61K51/10 ,  A61K51/1018 ,  A61K51/1036 ,  A61K51/1039 ,  A61K51/1045 ,  A61K51/1057 ,  A61K51/1072 ,  A61K2123/00 ,  B82Y5/00 ,  Y10S424/81 ,  Y10S530/868

Abstract: Provided are methods and compositions for detecting and treating normal, hypoplastic, ectopic or remnant tissue, organ or cells in a mammal. The method comprises parenterally injecting a mammalian subject, at a locus and by a route providing access to said tissue or organ, with an composition comprising antibody/fragment which specifically binds to targeted organ, tissue or cell. The antibody/fragment may be administered alone, or labeled or conjugated with an imaging, therapeutic, cytoprotective or activating agent.

公开(公告)号：US20050037005A1

公开(公告)日：2005-02-17

申请号：US10943442

申请日：2004-09-17

Applicant: Seth Lederman ,  Leonard Chess ,  Michael Yellin

Inventor： Seth Lederman ,  Leonard Chess ,  Michael Yellin

IPC: G01N33/50 ,  A61K35/76 ,  A61K38/00 ,  A61K38/17 ,  A61K39/00 ,  A61K39/395 ,  A61K47/48 ,  A61K48/00 ,  A61K49/00 ,  A61K51/10 ,  A61P3/10 ,  A61P5/14 ,  A61P7/04 ,  A61P7/06 ,  A61P17/06 ,  A61P19/02 ,  A61P21/04 ,  A61P29/00 ,  A61P31/14 ,  A61P35/00 ,  A61P35/02 ,  A61P37/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00 ,  C07K14/47 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/09 ,  C12N5/10 ,  C12N15/02 ,  C12N15/09 ,  C12N15/12 ,  C12N15/13 ,  C12P21/02 ,  C12P21/08 ,  C12Q1/02 ,  C12R1/91 ,  G01N33/15 ,  G01N33/53 ,  G01N33/566 ,  G01N33/574 ,  G01N33/577

CPC classification number: C07K14/705 ,  A61K38/00 ,  A61K39/00 ,  A61K47/68 ,  A61K47/6849 ,  A61K51/1039 ,  A61K51/1087 ,  A61K2123/00 ,  C07K14/70575 ,  C07K16/2875 ,  C07K2317/24 ,  C07K2319/00 ,  C12N5/0694 ,  Y02A50/401 ,  Y10S514/885

Abstract: This invention provides a monoclonal antibody which specifically recognizes and forms a complex with a protein located on the surface of activated T cells and thereby inhibits T cell activation of B cells. This invention also provides the monoclonal antibody 5c8 (ATCC Accession No. ______). This invention provides a human CD4− T cell leukemia cell line designated D1.1 (ATCC Accession No. ______) capable of constitutively providing contact-dependent helper function to B cells. This invention also provides an isolated protein from the surface of activated T cells, wherein the protein is necessary for T cell activation of B cells. This invention further provides an isolated, soluble protein from the surface of activated T cells, wherein the protein is necessary for T cell activation of B cells.

Abstract translation: 本发明提供了一种单克隆抗体，其特异性识别并与位于活化T细胞表面的蛋白质形成复合物，从而抑制B细胞的T细胞活化。 本发明还提供单克隆抗体5c8（ATCC登录号______）。 本发明提供了能够组成型地向B细胞提供接触依赖性辅助功能的人类CD4 + T细胞白血病细胞系D1.1（ATCC登录号______）。 本发明还提供了从活化的T细胞表面分离的蛋白质，其中所述蛋白质对B细胞的T细胞活化是必需的。 本发明还提供了从活化的T细胞的表面分离的可溶性蛋白质，其中所述蛋白质对B细胞的T细胞活化是必需的。

公开(公告)号：US06331175B1

公开(公告)日：2001-12-18

申请号：US09110181

申请日：1998-07-06

Applicant: Milton David Goldenberg

Inventor： Milton David Goldenberg

IPC: A61M2500

CPC classification number: G01R33/5601 ,  A61K49/16 ,  A61K51/10 ,  A61K51/1018 ,  A61K51/1036 ,  A61K51/1039 ,  A61K51/1045 ,  A61K51/1057 ,  A61K51/1072 ,  A61K2123/00 ,  B82Y5/00 ,  Y10S424/81 ,  Y10S530/868

Abstract: Provided are methods and compositions for detecting and treating normal, hypoplastic, ectopic or remnant tissue, organ or cells in a mammal. The method comprises parenterally injecting a mammalian subject, at a locus and by a route providing access to above-mentioned tissue or organ, with an composition comprising antibody/fragment which specifically binds to targeted organ, tissue or cell. The antibody/fragment may be administered alone, or labeled or conjugated with an imaging, therapeutic, cytoprotective or activating agent.

Abstract translation: 提供了用于检测和治疗哺乳动物中正常，发育不全，异位或残余组织，器官或细胞的方法和组合物。 该方法包括在一个位点和通过提供进入上述组织或器官的途径的哺乳动物受试者肠胃外注射包含特异性结合靶向的器官，组织或细胞的抗体/片段的组合物。 抗体/片段可以单独施用，或者与成像，治疗，细胞保护或活化剂标记或缀合。